1. According to head-to-head evidence, which of the following is true regarding the frequency of key adverse events with the second-generation BTKi acalabrutinib versus ibrutinib in the CLL setting?

2. You are managing a 70-year-old patient with symptomatic IGHV unmutated CLL who is experiencing persistent arthralgia while on therapy with ibrutinib despite dose holds and supportive care (assume the patient responded to therapy prior to experiencing toxicity). In collaboration with other team members, how do you manage this patient?

3. Assume you are managing a patient presenting with symptomatic unmutated IGHV TN CLL and a complex karyotype, some degree of renal insufficiency, as well as a history of cardiovascular risk factors. Working with other team members, how would you manage this patient?

4. Your patient with TN CLL and unmutated IGHV is preparing to receive treatment with the second-generation BTKi zanubrutinib. How would you counsel this patient on appropriate dosing?

5. Which statement is true regarding the efficacy of the non-covalent BTKi pirtobrutinib in pretreated patients with CLL?

6. Consider a patient with CLL preparing for therapy with ibrutinib; how would you address the potential for drug interactions with a moderate CYP3A inhibitor?

« Return to Activity